argenx SE (ARGX) Income Statement

NASDAQ: ARGXRevenue, profits, margins and EPS over 2 years.

ARGX 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+89.6%
$4.15B
2025 · hover or tap a bar for each year
2024: $2.19B2025: $4.15B (+89.6%)
20242025
Gross profit+88.6%
$3.70B
2025 · hover or tap a bar for each year
2024: $1.96B2025: $3.70B (+88.6%)
20242025
Operating income
$1.05B
2025 · hover or tap a bar for each year
2024: −$21.7M2025: $1.05B
20242025
Net income+55.1%
$1.29B
2025 · hover or tap a bar for each year
2024: $833.0M2025: $1.29B (+55.1%)
20242025
EPS (diluted)+1,192.7%
$19.52
2025 · hover or tap a bar for each year
2024: $1.512025: $19.52 (+1,192.7%)
20242025
Net profit margin−6.9 pts
31.1%
2025 · hover or tap a point for each year
2024: 38.0%2025: 31.1% (−6.9 pts)
20242025

ARGX revenue and net income

RevenueNet incomeNet margin (right axis)

Where ARGX's revenue goes

2025
Revenue
$4.15B100.0%
Cost of revenue
−$450.7M−10.9%
Gross profit
$3.70B89.1%
Research & development
−$1.36B−32.8%
Sales, general & admin
−$930.8M−22.4%
Other operating expenses
−$353.3M−8.5%
Operating income
$1.05B25.4%
Interest & other income
$224.0M5.4%
Income taxes
$13.4M0.3%
Net income
$1.29B31.1%

Each bar shows an amount and its share of revenue. ARGX kept 31.1% of revenue as net income.

ARGX profit margins

GrossOperatingNet

ARGX growth rates

to 2025
1 year3 years5 years10 years
Revenue+89.6%———
Gross profit+88.6%———
Operating income————
Net income+55.1%———
EPS (diluted)+1,192.7%———

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

ARGX quarterly EPS vs estimates

Reported EPSAnalyst estimate

argenx beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: October 22, 2026 (estimate $7.44).

ARGX income statement

argenx SE annual income statement
20252024
Revenue$4.15B$2.19B
Cost of revenue$450.7M$227.3M
Gross profit$3.70B$1.96B
Research & development$1.36B$983.4M
Sales, general & admin$930.8M$748.4M
Total operating expenses$2.65B$1.98B
Operating income$1.05B−$21.7M
Interest income$163.1M$138.7M
Interest expense$4.1M$2.2M
Income before taxes$1.28B$85.2M
Income taxes−$13.4M−$747.9M
Net income$1.29B$833.0M
EBITDA$1.31B$105.2M
EPS (diluted)$19.52$1.51
Gross margin89.1%89.6%
Operating margin25.4%−1.0%
Net margin31.1%38.0%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ARGX's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

ARGX financial results

In fiscal year 2025 (ended December 31, 2025), argenx reported revenue of $4.2 billion, up 89.6% from the year before. It had net income of $1.3 billion (up 55.1%), a net profit margin of 31.1%. Diluted earnings per share came to $19.52.

See the ARGX stock overview for the latest quote and news, or the ARGX chart for price history and technical indicators.

ARGX income statement FAQ

What is argenx's annual revenue?

argenx reported total revenue of $4.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 89.6% from $2.2 billion the previous year.

Is argenx profitable?

Yes. argenx reported net income of $1.3 billion in fiscal 2025, a net profit margin of 31.1%; its operating margin was 25.4%.

What is argenx's gross margin?

argenx's gross margin was 89.1% in fiscal 2025: for every $100 of revenue, argenx kept $89 after the direct cost of its products and services.

How much does argenx spend on research and development?

argenx spent $1.4 billion on research and development in fiscal 2025, 32.8% of revenue.

What are argenx's earnings per share?

argenx earned $19.52 per diluted share in fiscal 2025, compared with $1.51 a year earlier.

When will argenx report its next earnings?

argenx is expected to report results for the quarter ending September 30, 2026 on October 22, 2026 before the market opens.

When does argenx's fiscal year end?

argenx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.

Biotechnology income statements